Global preventive vaccines market will reach $120.07 billion by 2032, growing by 6.4% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 111 tables and 87 figures, this 211-page report “Global Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region.
Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases
By Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
By Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
For each region and country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and the breakdown of each national market by Vaccine Type, Disease, and Administration over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of Market Research Methodology 14
1.2.2 Market Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 16
1.2.6 Market Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 Market Overview and Dynamics 22
2.1 Market Size and Forecast 22
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the Market 27
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 29
2.2 Major Growth Drivers 33
2.3 Market Restraints and Challenges 39
2.4 Emerging Opportunities and Market Trends 42
2.5 Porter’s Fiver Forces Analysis 46
3 Segmentation of Global Market by Vaccine Type 50
3.1 Market Overview by Vaccine Type 50
3.2 Live/Attenuated Vaccines 52
3.3 Inactivated Vaccines 53
3.4 Subunit Vaccines 54
3.5 Toxoid Vaccines 55
3.6 Conjugate Vaccines 56
3.7 mRNA Vaccines 57
3.8 Recombinant Vector Vaccines 58
3.9 Other Vaccines 59
4 Segmentation of Global Market by Disease 60
4.1 Market Overview by Disease 60
4.2 Pneumococcal Disease 62
4.3 Poliovirus 63
4.4 Hepatitis 64
4.5 Influenza 65
4.6 Measles, Mumps, and Rubella (MMR) 66
4.7 Varicella 67
4.8 Human Papilloma Virus 68
4.9 COVID-19 69
4.10 Other Diseases 70
5 Segmentation of Global Market by Administration 71
5.1 Market Overview by Administration 71
5.2 Intramuscular Route 73
5.3 Subcutaneous Route 74
5.4 Oral Route 75
5.5 Intravenous Injection 76
5.6 Other Administration Routes 77
6 Segmentation of Global Market by Patient 78
6.1 Market Overview by Patient 78
6.2 Pediatric Vaccines 80
6.3 Adult Vaccines 82
7 Segmentation of Global Market by Region 84
7.1 Geographic Market Overview 2022-2032 84
7.2 North America Market 2022-2032 by Country 88
7.2.1 Overview of North America Market 88
7.2.2 U.S. 92
7.2.3 Canada 96
7.2.4 Mexico 99
7.3 European Market 2022-2032 by Country 102
7.3.1 Overview of European Market 102
7.3.2 Germany 106
7.3.3 U.K. 109
7.3.4 France 112
7.3.5 Spain 115
7.3.6 Italy 118
7.3.7 Russia 121
7.3.8 Rest of European Market 124
7.4 Asia-Pacific Market 2022-2032 by Country 126
7.4.1 Overview of Asia-Pacific Market 126
7.4.2 Japan 130
7.4.3 China 134
7.4.4 Australia 137
7.4.5 India 140
7.4.6 South Korea 143
7.4.7 Rest of APAC Region 146
7.5 South America Market 2022-2032 by Country 148
7.5.1 Argentina 151
7.5.2 Brazil 154
7.5.3 Chile 157
7.5.4 Rest of South America Market 160
7.6 MEA Market 2022-2032 by Country 161
7.6.1 UAE 164
7.6.2 Saudi Arabia 167
7.6.3 South Africa 170
7.6.4 Other National Markets 173
8 Competitive Landscape 174
8.1 Overview of Key Vendors 174
8.2 New Product Launch, Partnership, Investment, and M&A 177
8.3 Company Profiles 178
AstraZeneca plc 178
Bavarian Nordic A/S 180
China National Biotec Group Company Ltd. 183
CSL Ltd. 185
Daiichi Sankyo Co. Ltd 187
Emergent BioSolutions Inc. 189
GlaxoSmithKline plc 191
Johnson & Johnson 195
Merck & Co. 197
Moderna Inc. 199
Novavax, Inc. 200
Pfizer Inc. 202
Sanofi SA 206
Takeda Pharmaceutical Co. Ltd. 209
RELATED REPORTS 211
List of Tables:
Table 1. Snapshot of Global Preventive Vaccines Market in Balanced Perspective, 2022-2032 20
Table 2. World Economic Outlook, 2021-2031 25
Table 3. World Economic Outlook, 2021-2023 26
Table 4. Scenarios for Economic Impact of Ukraine Crisis 30
Table 5. World Health Spending by Region, $ bn, 2013-2020 38
Table 6. Main Product Trends and Market Opportunities in Global Preventive Vaccines Market 42
Table 7. Global Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 50
Table 8. Global Preventive Vaccines Market by Disease, 2022-2032, $ mn 60
Table 9. Global Preventive Vaccines Market by Administration, 2022-2032, $ mn 71
Table 10. Global Preventive Vaccines Market by Patient, 2022-2032, $ mn 78
Table 11. Global Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn 81
Table 12. Global Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn 83
Table 13. Global Preventive Vaccines Market by Region, 2022-2032, $ mn 85
Table 14. Leading National Preventive Vaccines Market, 2022 and 2032, $ mn 87
Table 15. North America Preventive Vaccines Market by Country, 2022-2032, $ mn 90
Table 16. U.S. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 94
Table 17. U.S. Preventive Vaccines Market by Disease, 2022-2032, $ mn 94
Table 18. U.S. Preventive Vaccines Market by Administration, 2022-2032, $ mn 95
Table 19. Canada Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 97
Table 20. Canada Preventive Vaccines Market by Disease, 2022-2032, $ mn 97
Table 21. Canada Preventive Vaccines Market by Administration, 2022-2032, $ mn 98
Table 22. Mexico Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 100
Table 23. Mexico Preventive Vaccines Market by Disease, 2022-2032, $ mn 100
Table 24. Mexico Preventive Vaccines Market by Administration, 2022-2032, $ mn 101
Table 25. Europe Preventive Vaccines Market by Country, 2022-2032, $ mn 105
Table 26. Germany Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 107
Table 27. Germany Preventive Vaccines Market by Disease, 2022-2032, $ mn 107
Table 28. Germany Preventive Vaccines Market by Administration, 2022-2032, $ mn 108
Table 29. U.K. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 110
Table 30. U.K. Preventive Vaccines Market by Disease, 2022-2032, $ mn 110
Table 31. U.K. Preventive Vaccines Market by Administration, 2022-2032, $ mn 111
Table 32. France Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 113
Table 33. France Preventive Vaccines Market by Disease, 2022-2032, $ mn 113
Table 34. France Preventive Vaccines Market by Administration, 2022-2032, $ mn 114
Table 35. Spain Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 116
Table 36. Spain Preventive Vaccines Market by Disease, 2022-2032, $ mn 116
Table 37. Spain Preventive Vaccines Market by Administration, 2022-2032, $ mn 117
Table 38. Italy Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 119
Table 39. Italy Preventive Vaccines Market by Disease, 2022-2032, $ mn 119
Table 40. Italy Preventive Vaccines Market by Administration, 2022-2032, $ mn 120
Table 41. Russia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 122
Table 42. Russia Preventive Vaccines Market by Disease, 2022-2032, $ mn 122
Table 43. Russia Preventive Vaccines Market by Administration, 2022-2032, $ mn 123
Table 44. Preventive Vaccines Market in Rest of Europe by Country, 2022-2032, $ mn 125
Table 45. APAC Preventive Vaccines Market by Country, 2022-2032, $ mn 128
Table 46. Japan Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 132
Table 47. Japan Preventive Vaccines Market by Disease, 2022-2032, $ mn 132
Table 48. Japan Preventive Vaccines Market by Administration, 2022-2032, $ mn 133
Table 49. China Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 135
Table 50. China Preventive Vaccines Market by Disease, 2022-2032, $ mn 135
Table 51. China Preventive Vaccines Market by Administration, 2022-2032, $ mn 136
Table 52. Australia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 138
Table 53. Australia Preventive Vaccines Market by Disease, 2022-2032, $ mn 138
Table 54. Australia Preventive Vaccines Market by Administration, 2022-2032, $ mn 139
Table 55. India Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 141
Table 56. India Preventive Vaccines Market by Disease, 2022-2032, $ mn 141
Table 57. India Preventive Vaccines Market by Administration, 2022-2032, $ mn 142
Table 58. South Korea Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 144
Table 59. South Korea Preventive Vaccines Market by Disease, 2022-2032, $ mn 144
Table 60. South Korea Preventive Vaccines Market by Administration, 2022-2032, $ mn 145
Table 61. Preventive Vaccines Market in Rest of APAC by Country/Region, 2022-2032, $ mn 147
Table 62. South America Preventive Vaccines Market by Country, 2022-2032, $ mn 150
Table 63. Argentina Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 152
Table 64. Argentina Preventive Vaccines Market by Disease, 2022-2032, $ mn 152
Table 65. Argentina Preventive Vaccines Market by Administration, 2022-2032, $ mn 153
Table 66. Brazil Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 155
Table 67. Brazil Preventive Vaccines Market by Disease, 2022-2032, $ mn 155
Table 68. Brazil Preventive Vaccines Market by Administration, 2022-2032, $ mn 156
Table 69. Chile Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 158
Table 70. Chile Preventive Vaccines Market by Disease, 2022-2032, $ mn 158
Table 71. Chile Preventive Vaccines Market by Administration, 2022-2032, $ mn 159
Table 72. MEA Preventive Vaccines Market by Country, 2022-2032, $ mn 163
Table 73. UAE Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 165
Table 74. UAE Preventive Vaccines Market by Disease, 2022-2032, $ mn 165
Table 75. UAE Preventive Vaccines Market by Administration, 2022-2032, $ mn 166
Table 76. Saudi Arabia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 168
Table 77. Saudi Arabia Preventive Vaccines Market by Disease, 2022-2032, $ mn 168
Table 78. Saudi Arabia Preventive Vaccines Market by Administration, 2022-2032, $ mn 169
Table 79. South Africa Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 171
Table 80. South Africa Preventive Vaccines Market by Disease, 2022-2032, $ mn 171
Table 81. South Africa Preventive Vaccines Market by Administration, 2022-2032, $ mn 172
Table 82. AstraZeneca plc: Company Snapshot 178
Table 83. AstraZeneca plc: Business Segmentation 179
Table 84. AstraZeneca plc: Product Portfolio 179
Table 85. Bavarian Nordic A/S: Company Snapshot 180
Table 86. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 181
Table 87. China National Biotec Group Company Ltd.: Company Snapshot 183
Table 88. CSL Ltd.: Company Snapshot 185
Table 89. Daiichi Sankyo Co. Ltd.: Company Snapshot 187
Table 90. Emergent BioSolutions Inc.: Company Snapshot 189
Table 91. GlaxoSmithKline: Company Snapshot 191
Table 92. GlaxoSmithKline: Business Segmentation 192
Table 93. GlaxoSmithKline: Product Portfolio 193
Table 94. GlaxoSmithKline: Revenue, 2018-2020, $ bn 194
Table 95. GlaxoSmithKline: Recent Developments 194
Table 96. Johnson & Johnson: Company Snapshot 195
Table 97. Johnson & Johnson: Business Segments 196
Table 98. Merck & Co., Inc.: Company Snapshot 197
Table 99. Merck & Co., Inc.: Business Segmentation 197
Table 100. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 198
Table 101. Moderna Inc.: Company Snapshot 199
Table 102. Novavax, Inc.: Company Snapshot 200
Table 103. Pfizer Inc.: Company Snapshot 202
Table 104. Pfizer Inc.: Business Segmentation 203
Table 105. Pfizer Inc.: Product Portfolio 204
Table 106. Pfizer Inc.: Revenue, 2018-2020, $ bn 205
Table 107. Pfizer Inc.: Recent Developments 205
Table 108. Sanofi: Company Snapshot 206
Table 109. Sanofi: Business Segmentation 206
Table 110. Sanofi: Revenue, 2018-2020, $ bn 208
Table 111. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 209
